

Pd(II)-Catalyzed alkyne annulation through allylic isomerization: Synthesis of spiro-cyclopentadiene pyrazolones

Sumi Changmai,^a Sabera Sultana,^a Bipul Sarma,^b and Sanjib Gogoi^{a*}

^aChemical Sciences & Technology Division, CSIR-North East Institute of Science and Technology, Jorhat-785006, AcSIR-Ghaziabad-201002, India, Fax: +913762370011 Tel.: +913762372948; skgogoi1@gmail.com; sanjibgogoi@neist.res.in. ^bDepartment of Chemical Sciences, Tezpur University, Napaam, Tezpur-784028, India.

Supporting Information

Contents


General Experiment	3
Experimental Procedures	3-8
Characterization Data	9-21
Spectra of NMR & HRMS	22-79
NOE Spectra	80-85
X-ray data	86

1. General Information

Melting points were measured with a Buchi B-540 melting point apparatus and are uncorrected. NMR spectra were recorded on Bruker Avance III 500 MHz FT NMR & Jeol Resonance ECZ 400 MHz FT NMR spectrometer using tetramethylsilane (TMS) as an internal standard. All the commercially available reagents were used as received. All experiments were monitored by thin layer chromatography. TLC was performed on Merck TLC Silica gel 60 F254 precoated plates. Column chromatography was performed on silica gel of 100-200 mesh obtained from Merck. HRMS data were recorded by electron spray ionization with a Q-TOF mass analyzer. Photophysical properties were evaluated on HITACHI (U-3900) UV-Vis spectrophotometer and Horiba (Fluorolog-3) fluorescence spectrophotometer

2. Reaction Procedures

2.1 General procedure for the synthesis of antipyrene derivatives (**1**)¹




Scheme SI-1: Synthesis of antipyrene derivatives

Preparation of antipyrene (1): 2-Phenyl pyrazolones were synthesized by following a known procedure.¹ To a stirred solution of 2-phenyl pyrazolone (1.0 equiv), in acetonitrile (4.0 mL), methyl iodide/alkyl iodide (5.0 equiv) was added. The reaction mixture was heated in a sealed tube for 12 h. The solvent was removed under vacuo and the crude reaction mixture was purified by alumina column chromatography using EtOAc as the eluent to afford antipyrenes **1**.

2.2. Optimization of the reaction conditions for the synthesis of compound **3aa**

Table SI-1 Optimization of the reaction conditions for **3aa**^a



Entry	Catalyst	Additive	Solvent	3aa (%) ^b
1	[{RuCl ₂ (<i>p</i> -cymene)} ₂]	Cu(OAc) ₂ ·H ₂ O	1,4-Dioxane	0
2	[RhCp*Cl ₂] ₂	Cu(OAc) ₂ ·H ₂ O	1,4-Dioxane	0
3	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	1,4-Dioxane	48
4	PdCl ₂	Cu(OAc) ₂ ·H ₂ O	1,4-Dioxane	0
5	Pd(OAc) ₂	AgOAc	1,4-Dioxane	20
6	Pd(OAc) ₂	CsOAc	1,4-Dioxane	36
7	Pd(OAc) ₂	NaOAc	1,4-Dioxane	38
8	Pd(OAc) ₂	KOAc	1,4-Dioxane	45
9	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	Toluene	74
10	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	MeCN	15
11	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	^t AmOH	79
12 ^[c]	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	MeOH	47
13	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	DMF	0
14	Pd(OAc) ₂	Cu(OAc) ₂ ·H ₂ O	DMSO	0

^aReaction conditions: **1a** (0.5 mmol), **2a** (1.0 mmol), catalyst (5.0 mol %), additive (0.5 mmol) and solvent (5.0 mL) at 90 °C under air for 8 h; unless otherwise mentioned. ^bIsolated yields. ^cReaction was performed at 64 °C.

2.3 General procedure for the synthesis of spiro-pyrazolone derivatives 3

A mixture of antipyrine (**1**, 0.5 mmol), alkyne (**2**, 1.0 mmol), Pd(OAc)₂ (5.0 mol %) and Cu(OAc)₂.H₂O (0.5 mmol) in *t*AmOH (5.0 mL) was stirred at 90 °C under open air for 8 hours. The solvent *t*AmOH was removed under vacuo and the crude reaction mixture was poured into water and extracted with ethylacetate (25 mL x 2). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 5% EtOAc in hexane as the eluent to afford spiro-pyrazolones **3**.

2.4 General procedure for one pot synthesis of spiro-pyrazolone derivatives 4


A mixture of antipyrine (**1**, 0.5 mmol), alkyne (**2**, 1.0 mmol), Pd(OAc)₂ (5.0 mol %) and Cu(OAc)₂.H₂O (0.5 mmol) in toluene (5.0 mL) was stirred at 90 °C for 8 hours. Then Lawessons reagent (1.5 equiv) was added and the mixture was again stirred at 90 °C for 6 hours. The solvent toluene was removed under vacuo and the crude reaction mixture was poured into water and extracted with ethylacetate (25 mL x 2). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 5% EtOAc in hexane as the eluant to afford spiro-pyrazolones **4**.

2.5 General procedure for the two-steps synthesis of spiro-pyrazolone derivatives 4

A mixture of olefinic product (**3**, 0.5 mmol) and Lawesson's reagent (1.0 equiv) was refluxed for 6 hours using toluene (5.0 mL) as the solvent. The solvent was removed under vacuo and the crude reaction mixture was poured into water and extracted with ethylacetate (25 mL x 2). The organic layer was then washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 5% EtOAc in hexane as the eluent to afford spiro-pyrazolones **4**.

3. Transformation of spiro-pyrazolone 3aa

(i) Synthesis of 3,4-dimethyl-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (4a) and 3,4-dimethyl-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]non-6-en-1-one (4b):




Scheme SI-2

To a stirred solution of **3aa** (54 mg, 0.1 mmol) in MeOH (8 mL), Pd/C 10 wt % (5 mg) was added. The reaction mixture was then stirred at room temperature for 12 hours under H₂ (60 psi). After completion of the reaction, the reaction mixture was filtered through a celite pad and the celite pad was washed with methanol (20 mL). The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 5% hexane in ethyl acetate as the eluent to afford **4a** (34 mg, 63%) and **4b** (10 mg, 18%).

Compound **4a**: White solid. M.p.: 156–159 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.24–6.90 (m, 25H), 3.24 (q, *J* = 5.5 Hz, 1H), 2.20 (s, 3H), 1.27 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 167.6, 147.6, 146.9, 143.1, 142.1, 136.1, 135.9, 135.4, 135.0, 130.7, 130.2, 130.1, 128.4, 128.2, 127.5, 127.4, 127.3, 127.1, 126.7, 126.6, 126.2, 124.0, 74.2, 66.1, 29.6, 11.8. HRMS (+ESI) Calcd for C₃₉H₃₃N₂O [M+H]⁺: 545.2593; found: 545.2634.

Compound **4b**: White solid. M.p.: 154–156 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.38–7.35 (m, 2H), 7.23–6.98 (m, 23H), 4.91 (d, *J* = 10.0 Hz, 1H), 3.90 (d, *J* = 10.0 Hz, 1H), 2.98 (q, *J* = 7.9 Hz, 1H), 2.10 (s, 3H), 1.26 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.2, 145.6, 139.8, 139.2, 137.5, 136.4, 136.2, 136.1, 132.1, 131.3, 129.8, 129.4, 128.5, 127.9, 127.6, 127.3, 126.9, 126.8, 126.7, 126.0, 123.8, 70.7, 66.8, 58.2, 57.9, 43.1, 12.4. HRMS (+ESI) Calcd for C₃₉H₃₅N₂O [M+H]⁺: 547.2749; found: 547.2817.


(ii) **Synthesis of 3,4-dimethyl-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (4a):**



Scheme SI-3

To a solution of **3aa** (108 mg, 0.2 mmol) in anhydrous THF, a solution of $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$ (0.2 mL, 2 M solution in THF, 0.4 mmol) was added at 0 °C and the reaction was stirred at room temperature for 12 h. The solvent was removed under vacuo and to the crude product MeOH was added. Then 10 wt % of Pd/C (10 mg) was added into the reaction mixture under nitrogen atmosphere. The reaction mixture was stirred again at room temperature for 24 h. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 5% hexane in ethylacetate as the eluent to afford **4a** (47 mg, 43%).

(iii) Synthesis of **4-(dibromomethylene)-3-methyl-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (4c)**:



Scheme SI-4

To a solution of **3aa** (108 mg, 0.2 mmol) in anhydrous CH_2Cl_2 , Br_2 (64 mg, 0.40 mmol) was added and then the reaction was continued to stir at room temperature for 12 h. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 2% hexane in EtOAc as the eluent to afford **4c** (103 mg, 74%). Pale yellow solid. M.p.: 159-162 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.54 (d, $J = 8.5$ Hz, 2H), 7.36 (t, $J = 7.9$ Hz, 2H), 7.20–7.05 (m, 17H), 6.96–6.95 (m, 4H), 2.32 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.5, 147.9, 145.6, 139.4, 135.4, 134.6, 134.5, 129.7, 129.3, 129.0, 128.1, 127.5, 127.4, 127.0, 126.1, 121.4, 73.9, 41.4, 29.6. HRMS (+ESI) Calcd for $\text{C}_{39}\text{H}_{29}\text{Br}_2\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 699.0647; found: 699.0689.

4. Measurement of fluorescence quantum yield (Φ_F)

Fluorescence quantum yields (Φ_F) of the compounds were calculated using quinine sulfate (0.5 M H_2SO_4 solution) as a standard ($\Phi = 0.54$). Emission spectra of all the compounds were recorded from 360 to 660 nm with excitation at 340 nm. Absorbance (optical density, OD) of all the samples were recorded at 340 nm and quantum yields were calculated according to equation (1), in which Φ_{ref} is the quantum yield of the reference, A_{sample} and A_{ref} are the areas

under the emission spectra of the dimers and the reference, OD_{ref} and OD_{sample} are the absorbances of the reference and the dimers which were measured at the excitation wavelength; n_{sample} and n_{ref} are the refractive indices of the dimers and the reference in solution.

$$\Phi F = \Phi_{ref} \left(\frac{A_{sample}}{A_{ref}} \right) \times \left(\frac{OD_{ref}}{OD_{sample}} \right) \times \left(\frac{n_{ref}}{n_{sample}} \right) \quad (1)$$



Sl. No	Compound	λ_{max} (nm)	λ_{em} (nm)	$(\Phi F)^{a,b}$
1	4aa	347	449	0.48
2	4ab	341	457	0.75
3	4ad	340	450	0.64
4	4ca	340	450	0.52
5	4da	318	450	0.61
6	4fa	340	449	0.30
7	4ga	345	438	0.47




^aConcentration 2.0×10^{-5} M in toluene; ^bAll the compounds were excited at 340 nm.



Reference:


1. S. Baruah, P. Saikia, G. Duarah and S. Gogoi, *Org. Lett.*, 2018, **20**, 3753–3757.

Spectral and Analytical Data of 3ba-ka and 3aa-ak:

 <p style="text-align: center;">3aa</p>	<p>3-Methyl-4-methylene-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3aa): The title compound was prepared by following the general procedure 2.3 from antipyrine, 1a (94 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol), which was then purified by column chromatography using 5% EtOAc in hexane to afford white solid of 3aa (214 mg, 79%). M.p.: 143–145 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.32–6.96 (m, 25H), 4.50 (s, 2H), 2.46 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 167.0, 150.1, 146.1, 145.0, 136.1, 135.0, 130.4, 130.0, 129.1, 128.2, 127.9, 127.4, 127.2, 126.7, 123.3, 89.4, 74.4, 42.4. HRMS (+ESI) Calcd for C₃₉H₃₁N₂O [M+H]⁺: 543.2436; found: 543.2338.</p>
 <p style="text-align: center;">3ba</p>	<p>3-Methyl-4-methylene-6,7,8,9-tetraphenyl-2-(p-tolyl)-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ba): The title compound was prepared by following the general procedure 2.3 from antipyrine 1b (101 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown solid of 3ba (181 mg, 65%). M.p.: 91–94 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.22–7.06 (m, 20H), 6.96 (dd, <i>J</i> = 7.8, 1.5 Hz, 4H), 4.48 (s, 2H), 2.45 (s, 3H), 2.31 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.5, 149.9, 145.7, 144.6, 136.5, 134.8, 134.7, 133.2, 130.0, 129.7, 129.4, 127.8, 127.5, 127.1, 126.8, 123.3, 122.3, 88.8, 74.0, 42.0, 21.0. HRMS (+ESI) Calcd for C₄₀H₃₃N₂O [M+H]⁺: 557.2592; found: 557.2567.</p>


 <p style="text-align: center;">3ca</p>	<p>2-(3,4-Dimethylphenyl)-3-methyl-4-methylene-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ca): The titled compound was prepared by following the general procedure 2.3 from antipyryne 1c (108 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using using 5% EtOAc in hexane afford off white solid of 3ca (202 mg, 71 %). M.p.: 80–83 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.23–7.21 (m, 4H), 7.19–7.15 (m, 6H), 7.13–7.06 (m, 7H), 6.97–6.92 (m, 6H), 4.46 (d, <i>J</i> = 3.9 Hz, 2H), 2.45 (s, 3H), 2.21 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 166.9, 150.3, 146.0, 145.0, 137.5, 135.6, 135.1, 135.0, 133.8, 130.4, 130.1, 128.1, 127.8, 127.4, 127.1, 125.1, 121.4, 88.9, 74.4, 42.2, 20.0, 19.6. HRMS (+ESI) Calcd for C₄₁H₃₅N₂O [M+H]⁺: 571.2749; found: 571.2693.</p>
 <p style="text-align: center;">3da</p>	<p>2-(4-Isopropylphenyl)-3-methyl-4-methylene-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3da): The title compound was prepared by following the general procedure 2.3 from antipyryne 1d (112 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown solid of 3da (199 mg, 70% yield). M.p.: 83–87 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.23–7.20 (m, 4H), 7.17–7.13 (m, 10H), 7.11–7.06 (m, 6H), 6.97–6.95 (m, 4H), 4.49 (s, 2H), 2.87 (heptet, <i>J</i> = 7.0 Hz, 1H), 2.43 (s, 3H), 1.22 (d, <i>J</i> = 7.0 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 166.7, 150.3, 147.6, 146.0, 145.0, 135.1, 135.0, 133.6, 130.4, 130.0, 128.1, 127.8, 127.4, 127.1, 123.6, 89.3, 74.3, 42.4, 34.0, 24.2. HRMS (+ESI) Calcd for C₄₂H₃₇N₂O [M+H]⁺: 585.2905; found: 585.2861.</p>
 <p style="text-align: center;">3ea</p>	<p>2-(4-Fluorophenyl)-3-methyl-4-methylene-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ea): The title compound was prepared by following the general procedure 2.3 from antipyryne 1e (103 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3ea (179 mg, 64%). M.p.: 95–98 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.20–7.18 (m, 6H), 7.17–7.06 (m, 12H),</p>

	<p>7.02–6.95 (m, 6H), 4.50 (s, 2H), 2.45 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 167.2, 161.8 (d, $J = 245.0$ Hz), 149.8, 145.9, 144.6, 134.8 (d, $J = 18.8$ Hz), 132.0, 130.0 (d, $J = 37.5$ Hz), 129.8, 128.0 (d, $J = 37.5$ Hz), 127.3, 127.0, 125.1, 125.0, 115.9, 115.7 (d, $J = 22.5$ Hz), 89.4, 74.1, 42.2. HRMS (+ESI) Calcd for $\text{C}_{39}\text{H}_{30}\text{FN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 561.2342; found: 561.2330.</p>
 <p style="text-align: center;">3fa</p>	<p>2-(4-Chlorophenyl)-3-methyl-4-methylene-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3fa): The title compound was prepared by following the general procedure 2.3 from antipyridine, 1f (111 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3fa (181 mg, 63%). M.p.: 113–116 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.29–7.26 (m, 2H), 7.23–7.21 (m, 2H), 7.19–7.13 (m, 10H), 7.13–7.06 (m, 6H), 6.96–6.94 (m, 4H), 4.51 (dd, $J = 5.0, 2.2$ Hz, 2H), 2.47 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 167.1, 149.6, 145.9, 144.4, 134.6, 134.5, 134.4, 131.5, 130.0, 129.7, 128.8, 127.8, 127.5, 127.2, 126.9, 123.8, 89.5, 74.0, 42.3. HRMS (+ESI) Calcd for $\text{C}_{39}\text{H}_{30}\text{ClN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 577.2046; found: 577.2012.</p>
 <p style="text-align: center;">3ga</p>	<p>2-(3-Chlorophenyl)-3-methyl-4-methylene-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ga): The title compound was prepared by following the general procedure 2.3 from antipyridine, 1g (111 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3ga (161 mg, 56%). M.p.: 105–110 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.26–7.19 (m, 4H), 7.19–7.07 (m, 16H), 6.96–6.94 (m, 4H), 4.52 (dd, $J = 10.0, 2.0$ Hz, 2H), 2.49 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 167.7, 149.8, 146.2, 144.7, 137.4, 134.8, 134.7, 130.3, 130.0, 128.2, 127.9, 127.5, 127.2, 126.5, 122.6, 120.9, 89.9, 74.4, 42.7. HRMS (+ESI) Calcd for $\text{C}_{39}\text{H}_{30}\text{ClN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 577.2046; found: 577.2013.</p>





3ha



(E)-3-Methyl-2,6,7,8,9-pentaphenyl-4-propylidene-2,3-diazaspiro[4.4]nona-6,8-dien-1-one and (Z)-3-methyl-2,6,7,8,9-pentaphenyl-4-propylidene-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ha, E:Z = 3:1): The title compound was prepared by following the general procedure **2.3** from antipyrine **1h** (108 mg, 0.5 mmol) and alkyne **2a** (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford white solid of **3ha** (188 mg, 66%). M.p.: 156–160 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.60–7.30 (m, 4H), 7.22–7.05 (m, 17H), 6.98–6.94 (m, 4H), 4.98 (t, *J* = 7.4 Hz, 0.75H), 4.85 (t, *J* = 7.5 Hz, 0.25H), 2.37 (s, 2.25H), 2.18 (t, *J* = 7.5 Hz, 1.5H), 2.12 (t, *J* = 7.5 Hz, 0.5H), 2.08 (s, 0.75H), 1.00 (t, *J* = 6.5 Hz, 2.25H), 0.96 (t, *J* = 6.5 Hz, 0.75H). ¹³C NMR (125 MHz, CDCl₃) δ 166.5, 166.1, 146.1, 145.4, 145.0, 143.0, 141.0, 139.9, 136.1, 135.2, 135.0, 134.9, 134.8, 130.0, 129.8, 129.7, 129.5, 128.7, 127.8, 127.6, 127.5, 127.1, 127.0, 126.8, 126.7, 126.0, 125.6, 122.4, 121.7, 112.6, 111.5, 73.6, 44.0, 42.9, 20.3, 18.9, 14.4, 13.9. HRMS (+ESI) Calcd for C₄₁H₃₅N₂O [M+H]⁺: 571.2749; found: 571.2753.




3ia


3-Methyl-2,6,7,8,9-pentaphenyl-4-(propan-2-ylidene)-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ia): The title compound was prepared by following the general procedure **2.3** from antipyrine, **1i** (108 mg, 0.5 mmol) and alkyne **2a** (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of **3ia** (177 mg, 62%). M.p.: 156–159 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, *J* = 7.6 Hz, 2H), 7.34 (t, *J* = 7.9 Hz, 2H), 7.25–7.05 (m, 17H), 6.95 (d, *J* = 6.8 Hz, 4H), 2.0 (s, 3H), 1.73 (s, 3H), 1.71 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.2, 145.7, 143.6, 136.3, 135.0, 129.8, 129.4, 128.7, 127.8, 127.5, 127.0, 126.7, 125.4, 121.2, 116.7, 74.9, 43.0, 20.1, 17.9. HRMS (+ESI) Calcd for C₄₁H₃₅N₂O [M+H]⁺: 571.2749; found: 571.2784.

 <p style="text-align: center;">3ja</p>	<p>2-(4-Chlorophenyl)-3-methyl-6,7,8,9-tetraphenyl-4-(propan-2-ylidene)-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ja): The title compound was prepared by following the general procedure 2.3 from antipyrine 1j (125 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3ja (202 mg, 67%). M.p.: 166–170 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.62–7.60 (m, 2H), 7.31–7.29 (m, 2H), 7.12–7.06 (m, 16H), 6.94 (d, <i>J</i> = 6.9 Hz, 4H), 2.00 (s, 3H), 1.73 (s, 3H), 1.71 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.6, 145.8, 143.5, 134.9, 134.7, 130.3, 129.8, 128.8, 127.9, 127.5, 127.1, 126.7, 122.1, 117.2, 74.8, 43.0, 20.1, 17.8. HRMS (+ESI) Calcd for C₄₁H₃₄ClN₂O [M+H]⁺: 605.2359; found: 605.2364.</p>
 <p style="text-align: center;">3ka</p>	<p>3-Benzyl-4-methylene-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ka): The title compound was prepared by following the general procedure 2.3 from antipyrine, 1k (128 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3ka (238 mg, 77%). M.p.: 191–193 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.29–7.04 (m, 26H), 7.00–6.94 (m, 4H), 4.34 (d, <i>J</i> = 2.0 Hz, 1H), 4.15 (d, <i>J</i> = 2.0 Hz, 1H), 3.81 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 166.9, 148.6, 145.7, 144.4, 136.7, 135.8, 134.7, 134.6, 130.0, 129.8, 128.8, 128.3, 127.9, 127.8, 127.5, 127.2, 126.8, 126.6, 123.5, 89.7, 74.5, 59.0. HRMS (+ESI) Calcd for C₄₅H₃₅N₂O [M+H]⁺: 619.2749; found: 619.2725.</p>


 <p style="text-align: center;">3ab</p>	<p>3-Methyl-4-methylene-2-phenyl-6,7,8,9-tetra-<i>p</i>-tolyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ab): The title compound was prepared by following the general procedure 2.3 from antipyryne 1a (94 mg, 0.5 mmol) and alkyne 2b (206 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford yellow solid of 3ab (227 mg, 76%). M.p.: 112–115 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.32 (m, 3H), 7.19–7.16 (m, 2H), 7.08 (d, <i>J</i> = 8.1 Hz, 4H), 6.94 (d, <i>J</i> = 8.0 Hz, 4H), 6.89 (d, <i>J</i> = 8.0 Hz, 4H), 6.84 (d, <i>J</i> = 8.2 Hz, 4H), 4.47 (d, <i>J</i> = 2.0 Hz, 1H), 4.46 (d, <i>J</i> = 2.0 Hz, 1H), 2.45 (s, 3H), 2.26 (s, 6H), 2.24 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 167.2, 150.4, 145.4, 144.1, 136.5, 136.2, 135.9, 132.0, 131.9, 129.9, 129.5, 128.7, 128.5, 128.2, 126.1, 122.8, 88.8, 73.8, 42.3, 22.6. HRMS (+ESI) Calcd for C₄₃H₃₉N₂O [M+H]⁺: 599.3062; found: 599.3070.</p>
 <p style="text-align: center;">3ac</p>	<p>6,7,8,9-Tetrakis(4-methoxyphenyl)-3-methyl-4-methylene-2-phenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ac): The title compound was prepared by following the general procedure 2.3 from antipyryne, 1a (94 mg, 0.5 mmol) and alkyne 2c (238 mg, 1.0 mmol) which was then purified by column chromatography using 10% EtOAc in hexane to afford white solid of 3ac (232 mg, 70%). M.p.: 198–200 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.16 (m, 5H), 7.12 (d, <i>J</i> = 8.8 Hz, 4H), 6.87 (d, <i>J</i> = 8.8 Hz, 4H), 6.69 (d, <i>J</i> = 8.8 Hz, 4H), 6.64 (d, <i>J</i> = 8.7 Hz, 4H), 4.46 (d, <i>J</i> = 11.3 Hz, 2H), 3.73 (s, 12H), 2.50 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 167.7, 158.7, 158.5, 150.9, 144.9, 143.6, 136.2, 131.7, 131.2, 129.0, 127.8, 127.7, 126.5, 123.1, 113.6, 113.3, 89.0, 74.0, 55.2, 42.7. HRMS (+ESI) Calcd for C₄₃H₃₉N₂O₅ [M+H]⁺: 663.2858; found: 663.2833.</p>



6,7,8,9-Tetrakis(4-fluorophenyl)-3-methyl-4-methylene-2-phenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ad): The title compound was prepared by following the general procedure **2.3** from antipyryne, **1a** (94 mg, 0.5 mmol) and alkyne **2d** (214 mg, 1.0 mmol) which was then purified by column chromatography using 7% EtOAc in hexane to afford white solid of **3ad** (203 mg, 66%). M.p.: 190–194 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.33 (t, *J* = 7.8 Hz, 2H), 7.24–7.14 (m, 7H), 6.91–6.85 (m, 8H), 6.80 (t, *J* = 8.7 Hz, 4H), 4.52 (s, 1H), 4.44 (s, 1H), 2.51 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.5, 163.3 (d, *J* = 246.3 Hz), 162.1 (d, *J* = 246.3 Hz), 149.6, 144.9, 144.1, 135.8, 132.0, 131.9, 131.7, 130.6 (d, *J* = 2.5 Hz), 129.2, 127.0, 123.1, 115.5, 115.2 (d, *J* = 22.5 Hz), 115.2, 89.6, 74.5, 42.4. HRMS (+ESI) Calcd for C₃₉H₂₇F₄N₂O [M+H]⁺: 615.2059; found: 615.2382.




6,7,8,9-Tetrakis(3-fluorophenyl)-3-methyl-4-methylene-2-phenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ae): The title compound was prepared by following the general procedure **2.3** from antipyryne, **1a** (94 mg, 0.5 mmol) and alkyne **2e** (214 mg, 1.0 mmol) which was then purified by column chromatography using 7% EtOAc in hexane to afford white solid of **3ae** (224 mg, 73%). M.p.: 85-88 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.37–7.33 (m, 2H), 7.29–7.29 (m, 2H), 7.21 (t, *J* = 8.8 Hz, 1H), 7.16–7.08 (m, 4H), 6.99–6.85 (m, 8H), 6.75–6.73 (m, 2H), 6.68–6.65 (m, 2H), 4.56 (d, *J* = 2.4 Hz, 1H), 4.46 (d, *J* = 2.3 Hz, 1H), 2.53 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 171.1, 162.3 (d, *J* = 244.3 Hz), 162.2 (d, *J* = 244.8 Hz), 148.7, 144.8, 144.4, 136.0, 135.9 (d, *J* = 5.5 Hz), 135.8 (d, *J* = 5.5 Hz), 135.3, 129.6 (d, *J* = 8.3 Hz), 129.5 (d, *J* = 8.2 Hz), 128.9, 126.8, 125.5 (d, *J* = 18.6 Hz), 125.4 (d, *J* = 18.6 Hz), 122.9, 116.6 (d, *J* = 22.1 Hz), 116.2 (d, *J* = 22.2 Hz), 114.6 (d, *J* = 7.5 Hz), 114.5 (d, *J* = 7.5 Hz), 89.6, 74.1, 42.1. HRMS (+ESI) Calcd for C₃₉H₂₇F₄N₂O [M+H]⁺: 615.2059; found: 615.2056.



3af

3,6,8-Trimethyl-4-methylene-2,7,9-triphenyl-2,3-




diazaspiro[4.4]nona-6,8-dien-1-one (3ag): The title compound was prepared by following the general procedure **2.3** from antipyrine, **1a** (94 mg, 0.5 mmol) and alkyne **2g** (116 mg, 1.0 mmol) which was then purified by column chromatography using 7% EtOAc in hexane to afford brown gum of **3ag** (121 mg, 58%). ¹H NMR (500 MHz, CDCl₃) δ 7.46 (dd, *J* = 8.7, 1.1 Hz, 2H), 7.41–7.38 (m, 4H), 7.31–7.30 (m, 7H), 7.25–7.21 (m, 2H), 4.42 (d, *J* = 1.9 Hz, 1H), 4.20 (d, *J* = 1.9 Hz, 1H), 2.66 (s, 3H), 1.89 (s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 168.2, 151.0, 145.2, 141.9, 141.7, 141.6, 136.1, 135.6, 135.3, 129.5, 129.2, 128.9, 128.1, 127.2, 126.9, 126.3, 122.8, 88.1, 73.1, 42.4, 13.9, 11.5. HRMS (+ESI) Calcd for C₂₉H₂₇N₂O [M+H]⁺: 419.2123; found: 419.2127.





3ag

6,8-Diethyl-3-methyl-4-methylene-2,7,9-triphenyl-2,3-

diazaspiro[4.4]nona-6,8-dien-1-one (3ag): The title compound was prepared by following the general procedure **2.3** from antipyrine, **1a** (94 mg, 0.5 mmol) and alkyne **2h** (130 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford a gum of **3ah** (123 mg, 55%). ¹H NMR (500 MHz, CDCl₃) δ 7.40–7.19 (m, 15H), 4.45 (s, 0.75H), 4.35 (s, 0.25H), 4.25 (s, 0.75H), 4.22 (s, 0.25H), 2.58 (s, 2.25H), 2.45–2.35 (m, 1.5H), 2.35–2.30 (m, 1H), 2.29 (s, 0.75H), 2.24–2.27 (m, 1.5H), 1.14 (t, *J* = 10.0 Hz, 1.5H), 0.98 (t, *J* = 10.0 Hz, 2.25H), 0.74 (t, *J* = 10.0 Hz, 2.25H). ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 167.6, 150.5, 149.9, 147.7, 146.9, 143.4, 142.9, 137.5, 136.1, 135.6, 132.9, 129.5, 129.3, 128.9, 128.6, 128.2, 128.0, 127.9, 127.9, 127.0, 126.1, 126.0, 122.9, 122.5, 88.8, 88.2, 74.1, 72.5, 42.3, 42.2, 19.9, 19.6, 14.8, 13.9. HRMS (+ESI) Calcd for C₃₁H₃₁N₂O [M+H]⁺: 447.2436; found: 447.2435


 <p style="text-align: center;">3ah</p>	<p>3-Methyl-4-methylene-2-phenyl-6,7,8,9-tetrapropyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ah): The title compound was prepared by following the general procedure 2.3 from antipyrene, 1a (94 mg, 0.5 mmol) and alkyne 2h (110 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown gum of 3ah (112 mg, 55%). ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.41 (t, <i>J</i> = 7.5 Hz, 2H), 7.21 (t, <i>J</i> = 7.0 Hz, 1H), 4.38 (d, <i>J</i> = 1.6 Hz, 1H), 3.93 (d, <i>J</i> = 1.7 Hz, 1H), 2.89 (s, 3H), 2.22–2.18 (m, 8H), 1.47–1.43 (m, 8H), 0.92 (t, <i>J</i> = 7.5 Hz, 6H), 0.83 (t, <i>J</i> = 7.0 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 152.0, 143.9, 142.0, 136.4, 128.8, 125.7, 122.1, 86.8, 70.8, 42.2, 28.0, 23.0, 22.2, 14.6, 14.2. HRMS (+ESI) Calcd for C₂₇H₃₉N₂O [M+H]⁺: 407.3062; found: 407.3084.</p>
 <p style="text-align: center;">3ai</p>	<p>6,7,8,9-Tetrabutyl-3-methyl-4-methylene-2-phenyl-2,3-diazaspiro[4.4]nona-6,8-dien-1-one (3ai): The title compounds were prepared by following the general procedure 2.3 from antipyrene, 1a (94 mg, 0.5 mmol) and alkyne 2i (138 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown gummy of 3ai (120 mg, 52%). ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (t, <i>J</i> = 7.0 Hz, 2H), 7.20 (t, <i>J</i> = 8.5 Hz, 1H), 4.38 (d, <i>J</i> = 1.6 Hz, 1H), 3.93 (d, <i>J</i> = 1.7 Hz, 1H), 2.9 (s, 3H), 2.27–2.16 (m, 8H), 1.44–1.22 (m, 16H), 0.92 (t, <i>J</i> = 7.5 Hz, 6H), 0.83 (t, <i>J</i> = 7.4 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 169.3, 152.1, 144.2, 142.0, 136.6, 128.8, 125.8, 122.2, 86.9, 71.0, 42.4, 36.6, 32.3, 31.1, 26.6, 25.8, 23.2, 22.9, 14.0, 13.9. HRMS (+ESI) Calcd for C₃₁H₄₇N₂O [M+H]⁺: 463.3688; found: 463.3619.</p>
 <p style="text-align: center;">4aa</p>	<p>4-Methyl-2,6,7,8,9-pentaphenyl-2,3-diazaspiro[4.4]nona-3,6,8-trien-1-one (4aa): To a solution of 3aa (100 mg, 0.18 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100–200 mesh) column chromatography using 3% EtOAc</p>

	<p>in hexane as the eluent to afford compound 4aa (89 mg, 47%). One pot synthesis of 4aa has been carried out by following the general procedure 2.4 from antipyrine, 1a (94 mg, 0.5 mmol) and alkyne 2a (178 mg, 1.0 mmol), which was then purified by column chromatography using 5% EtOAc in hexane to afford 4aa (153 mg, 29%). white solid, m.p.: 211-213 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.68 (d, <i>J</i> = 8.6 Hz, 2H), 7.35 (t, <i>J</i> = 8.5 Hz, 2H), 7.19–7.09 (m, 13H), 7.03–7.01 (m, 4H), 6.96 (d, <i>J</i> = 8.0 Hz, 4H), 2.06 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.6, 158.8, 149.2, 138.0, 137.7, 134.3, 133.5, 129.9, 128.8, 128.5, 128.4, 127.8, 127.6, 127.3, 125.4, 78.5, 14.0. HRMS (+ESI) Calcd for C₃₈H₂₉N₂O [M+H]⁺: 529.2274; found: 529.2198.</p>
	<p>4-Methyl-2-phenyl-6,7,8,9-tetra-p-tolyl-2,3-diazaspiro[4.4]nona-3,6,8-trien-1-one (4ab): To a solution of 3ab (100 mg, 0.17 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluent to afford compound 4ab (89 mg, 45%). One pot synthesis of 4ab has been carried out by following the general procedure 2.4 from antipyrine, 1a (94 mg, 0.5 mmol) and alkyne 2b (206 mg, 1.0 mmol), which was then purified by column chromatography using 5% EtOAc in hexane to afford 4ab (198 mg, 34%). White solid, m.p.: 196-200 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.72 (dd, <i>J</i> = 8.6, 1.0 Hz, 2H), 7.38–7.35 (m, 2H), 7.18 (t, <i>J</i> = 7.4 Hz, 1H), 7.0–6.88 (m, 12H), 6.88–6.80 (m, 4H), 2.27 (s, 6H), 2.21 (s, 6H), 2.04 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.0, 159.5, 148.7, 137.8, 137.2, 137.1, 136.8, 131.5, 130.8, 129.8, 129.0, 128.7, 128.5, 128.3, 125.2, 119.5, 78.3, 21.2, 21.1, 13.9. HRMS (+ESI) Calcd for C₄₂H₃₇N₂O [M+H]⁺: 585.2900; found: 585.2627.</p>





6,7,8,9-Tetrakis(4-fluorophenyl)-4-methyl-2-phenyl-2,3-


diazaspiro[4.4]nona-3,6,8-trien-1-one (4ad): To a solution of **3ab** (100 mg, 0.17 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluant to afford compound **4ad** (85.6 mg, 42%). One pot synthesis of **4ad** has been carried out by following the general procedure **2.4** from antipyrine, **1a** (94 mg, 0.5 mmol) and alkyne **2d** (214 mg, 1.0 mmol), which was then purified by column chromatography using 5% EtOAc in hexane to afford **4ad** (186 mg, 31%). White solid, m.p.: 185-189 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, *J* = 8.5 Hz, 2H), 7.37 (t, *J* = 8.5 Hz, 2H), 7.20 (t, *J* = 7.5 Hz, 1H), 6.99–6.97 (m, 4H), 6.92–6.80 (m, 12H), 2.05 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.1, 162.1 (d, *J* = 247.3 Hz), 162.0 (d, *J* = 247.3 Hz), 158.1, 147.8, 137.4, 137.2, 131.6 (d, *J* = 8.0 Hz), 130.1 (d, *J* = 8.1 Hz), 129.6 (d, *J* = 3.3 Hz), 129.6 (d, *J* = 3.5 Hz), 128.9, 125.7, 119.4, 115.7 (d, *J* = 21.4 Hz), 78.5, 14.1. HRMS (+ESI) Calcd for C₃₈H₂₅F₄N₂O [M+H]⁺: 601.1898; found: 601.1717.







2-(3,4-Dimethylphenyl)-4-methyl-6,7,8,9-tetraphenyl-2,3-



diazaspiro[4.4]nona-3,6,8-trien-1-one (4ca): To a solution of **3ca** (100 mg, 0.18 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluent to afford compound **4ca** (74 mg, 37%). One pot synthesis of **4ca** has been carried out by following the general procedure **2.4** from antipyrine, **1c** (94 mg, 0.5 mmol) and alkyne **2a** (138 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford **4ca** (155 mg, 28%). Sticky solid. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 2.3 Hz,


	<p>1H), 7.39 (dd, $J = 8.1, 2.4$ Hz, 1H), 7.19–6.94 (m, 21H), 2.24 (d, $J = 6.6$ Hz, 6H), 2.07 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.6, 158.7, 149.3, 138.2, 137.3, 135.7, 134.5, 134.2, 133.7, 130.2, 130.0, 128.7, 128.6, 128.4, 128.0, 127.8, 127.5, 121.1, 117.5, 78.7, 20.0, 19.4, 14.2. HRMS (+ESI) Calcd for $\text{C}_{40}\text{H}_{33}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 557.2587; found: 557.2446.</p>
	<p>2-(4-Isopropylphenyl)-4-methyl-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-3,6,8-trien-1-one (4da): To a solution of 3da (100 mg, 0.17 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluant to afford compound 4da (79 mg, 41%). One pot synthesis of 4da has been carried out by following the general procedure 2.4 from antipyrene, 1d (94 mg, 0.5 mmol) and alkyne 2a (138 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown gummy of 4da (159 mg, 28%). ^1H NMR (400 MHz, CDCl_3) δ 7.55 (d, $J = 8.6$ Hz, 2H), 7.21 (d, $J = 2.1$ Hz, 1H), 7.20 (d, $J = 1.9$ Hz, 1H), 7.17 – 7.01 (m, 17H), 6.96 (t, $J = 1.5$ Hz, 2H), 6.94 (d, $J = 1.7$ Hz, 2H), 3.00–2.80 (m, 1H), 2.06 (s, 3H), 1.22 (d, $J = 6.9$ Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3) δ 169.7, 158.8, 149.3, 146.4, 138.2, 135.6, 134.5, 133.7, 130.1, 128.7, 128.6, 128.4, 128.0, 127.8, 127.5, 126.9, 120.2, 78.6, 33.8, 24.1, 14.2. HRMS (+ESI) Calcd for $\text{C}_{41}\text{H}_{35}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 571.2744; found: 571.2837.</p>
	<p>2-(4-Chlorophenyl)-4-methyl-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-3,6,8-trien-1-one (4fa): To a solution of 3fa (100 mg, 0.17 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluant to afford compound 4fa (74 mg, 39%). One pot synthesis of 4fa has</p>



	<p>been carried out by following the general procedure 2.4 from antipyrine, 1f (94 mg, 0.5 mmol) and alkyne 2a (138 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford 4fa (146 mg, 26%). Sticky solid. ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, <i>J</i> = 2.2 Hz, 1H), 7.66 (d, <i>J</i> = 2.2 Hz, 1H), 7.27-7.24 (m, 2H), 7.23–6.92 (m, 20H), 2.06 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 159.4, 149.5, 138.8, 137.9, 134.5, 134.2, 133.4, 130.1, 129.9, 128.6, 128.5, 127.9, 127.8, 127.5, 125.2, 119.1, 117.0, 78.6, 14.1. HRMS (+ESI) Calcd for C₃₈H₂₈N₂OCl [M+H]⁺: 563.1885; found 563.1721.</p>
	<p>2-(3-Chlorophenyl)-4-methyl-6,7,8,9-tetraphenyl-2,3-diazaspiro[4.4]nona-3,6,8-trien-1-one (4ga): To a solution of 3aa (100 mg, 0.17 mmol) in anhydrous toluene (20 mL), Lawessons reagent (1.5 equiv) was added. The reaction mixture was then refluxed for 6 hours. The solvent was removed under vacuo and the crude product obtained was purified by silica gel (100-200 mesh) column chromatography using 3% EtOAc in hexane as the eluant to afford compound 4ga (68 mg, 36%). One pot synthesis of 4ga has been carried out by following the general procedure 2.4 from antipyrine, 1g (94 mg, 0.5 mmol) and alkyne 2a (138 mg, 1.0 mmol) which was then purified by column chromatography using 5% EtOAc in hexane to afford brown gummy of 4ga (140 mg, 25%). ¹H NMR (400 MHz, CDCl₃) δ 7.68 (s, 1H), 7.66 (s, 1H), 7.30 (d, <i>J</i> = 8.9 Hz, 2H), 7.16–7.07 (m, 12H), 6.900–6.92(m, 8H), 2.06 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 169.9, 159.4, 149.4, 138.8, 136.4, 134.3, 133.5, 130.6, 130.0, 128.9, 128.6, 128.0, 127.8, 127.6, 120.6, 78.6, 14.1. HRMS (+ESI) Calcd for C₃₈H₂₈N₂OCl [M+H]⁺: 563.1885; found 563.1707.</p>























-166.7174
 150.2543
 147.5612
 145.9509
 145.0403
 135.0687
 135.0150
 133.5939
 130.9587
 130.0425
 128.1328
 127.8436
 127.3895
 127.1429
 127.1100
 123.5691
 -89.2695
 -74.3357
 -42.4430
 -33.9854
 -27.1254
 -24.1480
 -14.3647






















































































































35695.1.fid
Name of Sample: SC-116
Spectrum No : 35695






164.4960
147.9440
145.6189
139.4048
135.3646
134.6322
134.5231
129.6627
129.2879
128.9504
128.1337
127.5443
127.4124
126.9860
126.1402
121.3591



73.9383


41.3945

29.6087

















33678
Name of Sample: SC-135
Spectrum No :33678





































NOE of compound **3ha**




Expanded form of NOE of **3ha**:

34017
SC 55-noe




NOE of **3ag**:




3ag (major isomer)



Significant interaction in NOE spectrum of compound **3ag**



NOE of **3ag** (Expanded form):




HMBC of 3ah:



3ah (major isomer)

Significant interaction in HMBC spectrum of compound 3ah

HMQC of 3ah:



X-Ray crystallographic data of compound 3aa: Empirical Formula- $C_{39}H_{30}N_2O$, $M = 542.65$, triclinic, Space group P-1, $a = 10.9996(6) \text{ \AA}$, $b = 12.1270(6) \text{ \AA}$, $c = 23.4345(12) \text{ \AA}$, $V = 3028.0(3) \text{ \AA}^3$, $Z = 4$, $T = 100 \text{ K}$, $\rho_{\text{calcd}} = 1.190 \text{ g/cm}^3$, $2\theta_{\text{max.}} = 28.819^\circ$, Refinement of 759 parameters on 7364 independent reflections with $wR_2 = 0.1920$ and $S = 0.937$. The crystal structure has been deposited at the Cambridge Crystallographic Data Centre (CCDC 1944638). The data can be obtained free of charge via the Internet at www.ccdc.cam.ac.uk/data_request.




Fig. S2 X-Ray Structure of Compound 3aa

X-Ray crystallographic data of compound 4aa: Empirical Formula- $C_{38}H_{28}N_2O$, $M = 528.62$, orthorhombic, Space group P-21, $a = 10.6306(8) \text{ \AA}$, $b = 15.1263(11) \text{ \AA}$, $c = 17.9884(14) \text{ \AA}$, $V = 2892.6(4) \text{ \AA}^3$, $Z = 4$, $T = 296(2) \text{ K}$, $\rho_{\text{calcd}} = 1.214 \text{ g/cm}^3$, $2\theta_{\text{max.}} = 25.000^\circ$, Refinement of 371 parameters on 5081 independent reflections with $wR_2 = 0.1127$ and $S = 1.024$. The crystal structure has been deposited at the Cambridge Crystallographic Data Centre (CCDC-2079413). The data can be obtained free of charge via the Internet at www.ccdc.cam.ac.uk/data_request.





Fig. S1 X-Ray Structure of Compound 4aa

3276
PPS_D2O_2ND



(H:D = 1.9:1)

